Neurocrine Biosciences, Inc. (NBIX)
| Market Cap | 16.96B +18.7% |
| Revenue (ttm) | 3.70B +38.0% |
| Net Income | 702.50M +64.1% |
| EPS | 6.73 +60.7% |
| Shares Out | 101.65M |
| PE Ratio | 24.77 |
| Forward PE | 13.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,494,266 |
| Open | 166.36 |
| Previous Close | 164.85 |
| Day's Range | 162.02 - 169.02 |
| 52-Week Range | 122.14 - 186.12 |
| Beta | 0.40 |
| Analysts | Strong Buy |
| Price Target | 207.50 (+24.39%) |
| Earnings Date | Nov 2, 2026 |
About NBIX
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical develo... [Read more]
Financial Performance
In 2025, Neurocrine Biosciences's revenue was $2.86 billion, an increase of 21.45% compared to the previous year's $2.36 billion. Earnings were $478.60 million, an increase of 40.23%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for NBIX stock is "Strong Buy." The 12-month stock price target is $207.5, which is an increase of 24.39% from the latest price.
News
Neurocrine price target raised to $224 from $207 at Guggenheim
Guggenheim raised the firm’s price target on Neurocrine (NBIX) to $224 from $207 and keeps a Buy rating on the shares.
Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress
SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its participation in the 2026 Neuroscience Education Institute (NEI) Fall Congress, taking place Nov...
Neurocrine price target raised to $175 from $165 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Neurocrine (NBIX) to $175 from $165 and keeps a Hold rating on the shares. The company reported a “beat and raise” Q3,…
Neurocrine price target raised to $190 from $187 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Neurocrine (NBIX) to $190 from $187 and keeps an Outperform rating on the shares after its Q3 earnings beat.
Neurocrine price target raised to $220 from $210 at Canaccord
Canaccord raised the firm’s price target on Neurocrine (NBIX) to $220 from $210 and keeps a Buy rating on the shares. The firm updated its model following Q3 results thst…
Neurocrine price target raised to $215 from $210 at Piper Sandler
Piper Sandler raised the firm’s price target on Neurocrine (NBIX) to $215 from $210 and keeps an Overweight rating on the shares. The firm notes Neurocrine reported Q3 diluted GAAP…
Neurocrine price target raised to $185 from $183 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Neurocrine (NBIX) to $185 from $183 and keeps an Equal Weight rating on the shares. Neurocrine posted record Q3 net product sales…
Neurocrine reports Q3 non-GAAP EPS $3.29, consensus $2.75
Reports Q3 revenue $1.123B, consensus $1.04B. “Our Q3 performance marks another important milestone in Neurocrine’s (NBIX) evolution, with net product sales exceeding $1B for the first time, driven by...
Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Neuroc...
Neurocrine Biosciences Earnings Call Transcript: Q3 2026
Record net product sales exceeded $1.1B, up more than 40% YoY, with all three products contributing. INGREZZA guidance rose, while 2027 growth is expected to offset pricing pressure; pipeline readouts and study starts make 2027 catalyst-rich.
Neurocrine Biosciences Earnings release: Q3 2026
Neurocrine Biosciences released its Q3 2026 earnings on November 2, 2026, summarizing the period's financial results.
Neurocrine Biosciences Quarterly report: Q3 2026
Neurocrine Biosciences has published its Q3 2026 quarterly earnings report on November 2, 2026.
Neurocrine Biosciences Slides: Q3 2026
Neurocrine Biosciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 2, 2026.
Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia
BootCAHmp® delivers evidence-based education to strengthen understanding of classic congenital adrenal hyperplasia through interactive learning and real-world patient cases DiscoverCAH™ provides immer...
Neurocrine presents new analysis establishing benchmark in dyskinesia treatment
Neurocrine (NBIX) announced new research that helps define clinically meaningful improvement in overall health reported by people living with tardive dyskinesia who were treated with Ingrezza – albena...
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with I...
Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome
Expert perspectives highlight the interaction of hypothalamic dysfunction, biological, behavioral, and environmental factors in shaping the challenges of hyperphagia in Prader-Willi syndrome for patie...
Neurocrine begins Phase 2 study of NBI-‘567 in adults with Alzheimer’s disease
Neurocrine (NBIX) announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 in adults with mild to moderate Alzheimer’s disease. NBI-‘567 is designed to directly a...
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in ...
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia
Decades of real-world medical records highlight the diverse challenges of living with classic congenital adrenal hyperplasia and how needs evolve from childhood through adulthood Patient records showe...
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
Conference Call and Webcast Scheduled for Monday, November 2 SAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarte...
Neurocrine price target lowered to $150 from $164 at BMO Capital
BMO Capital lowered the firm’s price target on Neurocrine (NBIX) to $150 from $164 and keeps a Market Perform rating on the shares as part of a broader research note…
Neurocrine assumed with a Buy at Guggenheim
Guggenheim analyst Delma Caiati assumed coverage of Neurocrine (NBIX) with a Buy rating and $207 price target Neurocrine has transitioned from a single-product story into “a diversified neuropsychiatr...
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
PWS-VISTA observational study will build longitudinal real-world evidence on VYKAT XR use for hyperphagia in Prader-Willi syndrome in routine clinical practice BRAVE-PWS observational study will captu...